Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.

Abstract

The pure anti-oestrogen fulvestrant has now been licensed for use in advanced breast cancer which has progressed on an anti-oestrogen. Optimal sequencing of various endocrine agents becomes very important in the therapeutic strategy. We report our experience of further endocrine response with another endocrine agent after prior fulvestrant treatment. Among… (More)

Topics

3 Figures and Tables

Cite this paper

@article{Cheung2006EndocrineRA, title={Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.}, author={Kwok Leung Cheung and Rachel Owers and John Robertson}, journal={Endocrine-related cancer}, year={2006}, volume={13 1}, pages={251-5} }